David Spetzler, president of Caris Life Sciences [Image: Caris Life Sciences]
Irving-based Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses—along with claims data to improve development strategies for Moderna’s oncology pipeline.